Genotypic Profiles of rpoB, katG and inhA Gene Mutations Associated With Mycobacterium tuberculosis Resistance in Multidrug-Resistant Tuberculosis Patients in Niger

Profils Génotypiques des Mutations des Gènes rpoB, katG et inhA Associées à la Résistance de Mycobacterium tuberculosis chez des Patients Atteints de Tuberculose Multirésistante au Niger

Authors

  • Djika Mamane 3. Laboratory of Genetics and Genomes Analysis, Faculty of Sciences and Technology, University of Abomey-Calavi. 01 PO Box526 Cotonou, Bénin.
  • Antoine Abel Missihoun 3. Laboratory of Genetics and Genomes Analysis, Faculty of Sciences and Technology, University of Abomey-Calavi. 01 PO Box526 Cotonou, Bénin.
  • Houssou Wilfried Milognon 3. Laboratory of Genetics and Genomes Analysis, Faculty of Sciences and Technology, University of Abomey-Calavi. 01 PO Box526 Cotonou, Bénin.
  • Charles Hornel Koudokpon 2. Research Unit in Applied Microbiology and Pharmacology of natural substances, Research Laboratory in Applied Biology, Polytechnic School of Abomey-Calavi, University of Abomey-Calavi, Cotonou, Benin, 01 PO Box 2009, Cotonou, Bénin.
  • Laouali Adamou I 4. Département de Biologie Faculté des Sciences et Techniques, Université Abdou Moumouni, BP : 10662, Niamey, Niger.
  • Tamègnon Victorien Dougnon 2. Research Unit in Applied Microbiology and Pharmacology of natural substances, Research Laboratory in Applied Biology, Polytechnic School of Abomey-Calavi, University of Abomey-Calavi, Cotonou, Benin, 01 PO Box 2009, Cotonou, Bénin.
  • Yacoubou Bakasso 4. Département de Biologie Faculté des Sciences et Techniques, Université Abdou Moumouni, BP : 10662, Niamey, Niger.
  • Honoré Sourou Bankole 2. Research Unit in Applied Microbiology and Pharmacology of natural substances, Research Laboratory in Applied Biology, Polytechnic School of Abomey-Calavi, University of Abomey-Calavi, Cotonou, Benin, 01 PO Box 2009, Cotonou, Bénin.
  • Clément Agbangla 3. Laboratory of Genetics and Genomes Analysis, Faculty of Sciences and Technology, University of Abomey-Calavi. 01 PO Box526 Cotonou, Bénin.

DOI:

https://doi.org/10.5281/hra.v2i10.6089

Keywords:

Mycobacterium tuberculosis, Specific mutations, Multiresistance, Niger

Abstract

 t

  ABSTRACT Introduction. In 2021, in Niger, among new cases, 9% of bacteriologically confirmed TB cases tested for rifampicin resistance; 81% of cases already treated and for all 79 cases of multidrug-resistant tuberculosis /rifampicin-resistant tuberculosis (MDR/RR-TB). The objective of this study is to determine the specific mutations in the rpoB, katG and inhA genes associated with the resistance of Mycobacterium tuberculosis to antituberculosis drugs in Niger. Methods. Sputum samples were collected from patients with rifampicin-resistant pulmonary tuberculosis and analyzed by the MTBDRplus 2.0 assay to determine the genetic profiles of mutations in the rpoB, katG and inhA genes associated with the multidrug resistance. Results. A total of 50 patients including 43 males (86%) were enrolled in the study. Mutations associated with multidrug resistance were detected in 6 patients (12%). They consist of S315T1 of the katG gene (30% of patients), C15T of the inhA gene (4% of patients) and H526D, S531L, H526D/H526Y of the rpoB gene (4% of patients each). Two areas of polymorphism (526-529 and 530-533) generated three types of mutations: MUT2A, MUT2B and MUT3 of which the combination of which was observed in 4% of patients. Three resistance genotypic profiles result from these mutations including RR-TB, HR-TB and MDR-TB. The TB-HR profile was predominant with 20% occurrence, but the TB-MR profile, observed in 12% of patients, remains worrying because it is more difficult to manage. Conclusion. Three genotypic profiles of resistance were observed, namely TB-RR, TB-Hr and TB-MR. The diagnostic strategy must now prepare the search of the TB-Hr genetic profile, which was moreover the most frequently detected in this study.   RESUME Introduction. En 2021, au Niger, parmi les nouveaux cas, 9% des cas de tuberculose bactériologiquement confirmés ont été testés pour la résistance à la rifampicine ; 81% des cas déjà traités et pour l'ensemble des 79 cas de tuberculose multirésistante/tuberculose résistante à la rifampicine (MDR/RR-TB). L'objectif de cette étude est de déterminer les mutations spécifiques des gènes rpoB, katG et inhA associées à la résistance de Mycobacterium tuberculosis aux médicaments antituberculeux au Niger. Méthodologie. Des échantillons d'expectoration ont été prélevés chez des patients atteints de tuberculose pulmonaire résistante à la rifampicine et analysés par le test MTBDRplus 2.0 afin de déterminer les profils génétiques des mutations des gènes rpoB, katG et inhA associées à la multirésistance aux médicaments. Résultats. Au total, 50 patients, dont 43 hommes (86 %), ont été inclus dans l'étude. Des mutations associées à la multirésistance ont été détectées chez 6 patients (12%). Il s'agit de S315T1 du gène katG (30 % des patients), C15T du gène inhA (4 % des patients) et H526D, S531L, H526D/H526Y du gène rpoB (4 % des patients chacun). Deux zones de polymorphisme (526-529 et 530-533) ont généré trois types de mutations : MUT2A, MUT2B et MUT3 dont la combinaison a été observée chez 4% des patients. Trois profils génotypiques de résistance résultent de ces mutations : TB-RR, TB-HR et TB-MR. Le profil TB-HR était prédominant avec 20% d'occurrence, mais le profil TB-MR, observé chez 12% des patients, reste préoccupant car plus difficile à prendre en charge. Conclusion. Trois profils génotypiques de résistance ont été observés, à savoir TB-RR, TB-Hr et TB-MR. La stratégie diagnostique doit maintenant préparer la recherche du profil génétique TB-Hr, qui était d'ailleurs le plus fréquemment détecté dans cette étude.

References

Misombo-Kalabela A, Georges N-T, Ginette C, Mireille K, Emmanuel AZ, Kimpanga D, Tshapenda P, Ilunga K, Serge BF, Nzanzu M, François-Xavier M-K. Facteurs de risque de la tuberculose multi-résistante dans la ville de Kinshasa en République Démocratique du Congo. Pan African Medical Journal 2016 23(157): 1-11.

Organisation Mondiale de la Santé. 2022. Global tuberculosis report. Licence: CC BY-NC-SA 3.0 IGO.

Organisation Mondiale de la Santé, 2020. Rapport sur la tuberculose dans le monde : résumé d’orientation. Organisation mondiale de la Santé. https://apps.who.int/iris/handle/10665/337571. Licence: CC BY-NC-SA 3.0 IGO.

Organisation Mondiale de la Santé, 2020. Profil Niger Tuberculose 2020. www.afro.who.int/fr/countries/niger. OMS : Bureau Niger

Blanchard, J.S. 1996. ‘Molecular mechanisms of drug resistance in Mycobacterium tuberculosis’, Annual review of biochemistry, 65(1), pp. 215–239.

Dean AS, Cox H and Zignol M. Epidemiology of Drug-Resistant Tuberculosis, Advances in Experimental Medicine and Biology In S. Gagneux (ed.), Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control, Advances in Experimental Medicine and Biology. pp 209-220. © Springer International Publishing AG 2017. Available at: https://doi.org/10.1007/978-3-319-64371-7_11.

Amala SE and Silas G. The prevalence of tuberculosis (TB) and multiple drug resistant tuberculosis (mdr-tb) in Bayelsa State, Nigeria. Journal of biomedical 2019 10 (3): 1-8.

Organisation Mondiale de la Santé, 2017. Cadre d’indicateurs et de cibles pour le renforcement des laboratoires en ligne avec la Stratégie pour mettre fin à la tuberculose. Genève : 2017. Licence : CC BY-NC-SA 3.0 IGO. OMS, 2017

Guillet-Caruba C, Martinez V, Doucet-Populaire F. Les nouveaux outils de diagnostic microbiologique de la tuberculose maladie. La Revue de médecine interne 35, 2014 794–800

Organisation Mondiale de la Santé, 2011. Mise en œuvre rapide du test diagnostique Xpert MTB/RIF: guide technique et opérationnel : considérations pratiques. WHO/HTM/TB/2011.2 ISBN 978 92 4 250156 8.

Rigouts L, Hoza AS, De Rijk P, Torrea G, Chonde TM, Basra D, Zignol M, Van Leth F, Egwaga SM, Van Deun A, Evaluation du test Genotype® MTBDRplus comme outil pour la surveillance de la résistance aux médicaments. INT J TUBERC LUNG DIS, 2011, 15(7) : 959–965.

Ilboudo D. Bisseye C, Djigma F, Diande S, Yonli A, Bazie J, Telesphore V, Compaore R, Gnoula C, Djibril T, Moret R, Pietra V, Karou D, Simplice MO, Simpore J. Diagnostic moléculaire du complexe Mycobacterium tuberculosis résistant à l’isoniazide et à la rifampicine au Burkina Faso. Pan Afr. Med. J. 2018 ; 30 (1) : 284-296. https://doi.org/10.11604/pamj.2018.30.284.15545.

Organisation Mondiale de la Santé, 2008. Rapport Tuberculose 2008. www.who.int/tb ISBN 978 92 4156354 3

Global Laboratory Initiative (GLI) 2017. Algorithmes de diagnostic de la tuberculose, Modèle de l’Initiative mondiale pour les laboratoires

Piubello A, Harouna S, Hassane Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, Van Deun A. Taux élevé de guérison sans rechute avec un traitement court standardisé de la tuberculose multirésistante au Niger. International Journal of Tuberculosis and Lung Disease 2014 ;18(1) : 1188–1194.

Wuyep VB, Ani A, Davou V, Fyaktuand E J, Obishakin E, Ikeh EI. Detection of Resistant-Associated Mutations and Genetic Profile of Resistance to Rifampicin and Isoniazid Among Multi-Drug Resistant Mycobacterium Tuberculosis Isolates from Plateau State. J Med Lab Sci 2019; 29(3): 72–85.

Ahmed S, Indu S, Nazish F, Sumit KV, Mohammad S, Uzma T. Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of northern India. International Journal of Mycobacteriology 2018; 7(4):315-325.

Diandé S, Ogbomon EO, and Gueye A. Occurrence of mutations associated with rifampicin and isoniazid resistant in Mycobacterium tuberculosis isolates from patients in Burkina Faso. Int J Mol Biol 2019; 4(3):106–111.

Organisation Mondiale de la Santé, 2021. Profil Niger Tuberculose 2021. www.afro.who.int/fr/countries/niger Bureau Niger.

Fourati SS, Mzid H, Marouane C, Kammoun S, Messadi-Akrout F. Tuberculose multirésistante: épidémiologie et facteurs de risque. Revue de Pneumologie Clinique 2015 ; 71(4) : 233–241.

Kabir S, Junaid K, and Rehman A. Variations in rifampicin and isoniazid resistance associated genetic mutations among drug naïve and recurrence cases of pulmonary tuberculosis. International Journal of Infectious Diseases 2021; 103(1):56–61.

Dia ML, Affolabi D, Ba F, Sanoussi N, Gueye PAL, Kâ R, Sarr M and Cissé MF. Genetic diversity and resistance profile of mycobacterial strains isolated in Senegal’, African Journal of Bacteriology Research 2019; 11(2) 7–13.

Kida IM, Garbati MA, Ummate I, Goni BW, Bakki B, Dayar AD, Yusuph H. Rifampicin Resistance Tuberculosis: Prevalence and Risk Factors among Pulmonary Tuberculosis Patients in Maiduguri. North eastern Nigeria Bo Med J 2017; 14(2): 190 - 196.

Luo D, Qiang C, Guangchu X, Yiping P, Tao L, Xiaowen C, Lingbing Z, Kaisen C, Prevalence and molecular characterization of multidrug-resistant M. tuberculosis in Jiangxi province. China Scientific reports 2019; 9(1): 1–8.

Diandé S, Ogbomon EO and Gueye A. Occurrence of mutations associated with rifampicin and isoniazid resistant in Mycobacterium tuberculosis isolates from patients in Burkina Faso. Int J Mol Biol 2019; 4(3):106–111.

Luo D, Qiang C, Guangchu X, Yiping P, Tao L, Xiaowen C, Lingbing Z, Kaisen C. Prevalence and molecular characterization of multidrug-resistant M. tuberculosis in Jiangxi province, China. Scientific reports 2019; 9(1): 1–8.

Sylverken AA, Kwarteng A, Twumasi-Ankrah S, Owusu M, Arthur RA, Dumevi RM. The burden of drug resistance tuberculosis in Ghana; results of the First National Survey. PLoS ONE 2021 ; 16(6): e0252819

Organisation Mondiale de la Santé, 2022. Profil Niger Tuberculose 2022. www.afro.who.int/fr/countries/niger. Bureau Niger

Downloads

Published

26-09-2024

How to Cite

Djika Mamane, Antoine Abel Missihoun, Houssou Wilfried Milognon, Charles Hornel Koudokpon, Laouali Adamou I, Tamègnon Victorien Dougnon, Yacoubou Bakasso, Honoré Sourou Bankole, & Clément Agbangla. (2024). Genotypic Profiles of rpoB, katG and inhA Gene Mutations Associated With Mycobacterium tuberculosis Resistance in Multidrug-Resistant Tuberculosis Patients in Niger: Profils Génotypiques des Mutations des Gènes rpoB, katG et inhA Associées à la Résistance de Mycobacterium tuberculosis chez des Patients Atteints de Tuberculose Multirésistante au Niger. HEALTH RESEARCH IN AFRICA, 2(10). https://doi.org/10.5281/hra.v2i10.6089

Issue

Vol. 2 No. 10 (2024): Health Research in Africa

Section

Research Articles

License

Copyright (c) 2024 Djika Mamane, Antoine Abel Missihoun, Houssou Wilfried Milognon, Charles Hornel Koudokpon, Laouali Adamou I, Tamègnon Victorien Dougnon, Yacoubou Bakasso, Honoré Sourou Bankole, Clément Agbangla

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License  CC BY-NC-ND 4.0  that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

 

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

 

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work